Phosphorylation Status of Thymidine Kinase 1 Following Antiproliferative Drug Treatment Mediates 3′-Deoxy-3′-[18F]-Fluorothymidine Cellular Retention

Background 3′-Deoxy-3′-[18F]-fluorothymidine ([18F]FLT) is being investigated as a Positron Emission Tomography (PET) proliferation biomarker. The mechanism of cellular [18F]FLT retention has been assigned primarily to alteration of the strict transcriptionally regulated S-phase expression of thymidine kinase 1 (TK1). This, however, does not explain how anticancer agents acting primarily through G2/M arrest affect [18F]FLT uptake. We investigated alternative mechanisms of [18F]FLT cellular retention involving post-translational modification of TK1 during mitosis. Methods [18F]FLT cellular retention was assessed in cell lines having different TK1 expression. Drug-induced phosphorylation of TK1 protein was evaluated by MnCl2-phos-tag gel electrophoresis and correlated with [18F]FLT cellular retention. We further elaborated the amino acid residues involved in TK1 phosphorylation by transient transfection of FLAG-pCMV2 plasmids encoding wild type or mutant variants of TK1 into TK1 negative cells. Results Baseline [18F]FLT cellular retention and TK1 protein expression were associated. S-phase and G2/M phase arrest caused greater than two-fold reduction in [18F]FLT cellular retention in colon cancer HCT116 cells (p<0.001). G2/M cell cycle arrest increased TK1 phosphorylation as measured by induction of at least one phosphorylated form of the protein on MnCl2-phos-tag gels. Changes in [18F]FLT cellular retention reflected TK1 phosphorylation and not expression of total protein, in keeping with the impact of phosphorylation on enzyme catalytic activity. Both Ser13 and Ser231 were shown to be involved in the TK1 phosphorylation-modulated [18F]FLT cellular retention; although the data suggested involvement of other amino-acid residues. Conclusion We have defined a regulatory role of TK1 phosphorylation in mediating [18F]FLT cellular retention and hence reporting of antiproliferative activity, with implications especially for drugs that induce a G2/M cell cycle arrest.

[1]  Eliot T. McKinley,et al.  Limits of [18F]-FLT PET as a Biomarker of Proliferation in Oncology , 2013, PloS one.

[2]  L. Carroll,et al.  Synthesis and evaluation of nucleoside radiotracers for imaging proliferation. , 2012, Nuclear medicine and biology.

[3]  J. Jacob,et al.  Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [(18)F] 3´-deoxy-3´-fluorothymidine PET: a pilot study. , 2012, Biomarkers in medicine.

[4]  J. Christensen,et al.  [18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells , 2011, Clinical Cancer Research.

[5]  L. Rosso,et al.  [18F]-3′Deoxy-3′-Fluorothymidine Positron Emission Tomography and Breast Cancer Response to Docetaxel , 2011, Clinical Cancer Research.

[6]  H. Vesselle,et al.  Tumor 3′-Deoxy-3′-18F-Fluorothymidine (18F-FLT) Uptake by PET Correlates with Thymidine Kinase 1 Expression: Static and Kinetic Analysis of 18F-FLT PET Studies in Lung Tumors , 2011, The Journal of Nuclear Medicine.

[7]  Karl A. Merrick,et al.  Switching Cdk2 on or off with small molecules to reveal requirements in human cell proliferation. , 2011, Molecular cell.

[8]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[9]  S. Shousha,et al.  Altered Tissue 3′-Deoxy-3′-[18F]Fluorothymidine Pharmacokinetics in Human Breast Cancer following Capecitabine Treatment Detected by Positron Emission Tomography , 2009, Clinical Cancer Research.

[10]  S. Yao,et al.  The Role of Human Nucleoside Transporters in Uptake of 3′-Deoxy-3′-fluorothymidine , 2008, Molecular Pharmacology.

[11]  P. Workman,et al.  Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901 , 2008, Molecular Cancer Therapeutics.

[12]  S. Elledge,et al.  A quantitative atlas of mitotic phosphorylation , 2008, Proceedings of the National Academy of Sciences.

[13]  J. Bading,et al.  Imaging of Cell Proliferation: Status and Prospects , 2008, Journal of Nuclear Medicine.

[14]  P. Workman,et al.  Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity , 2007, Molecular Cancer Therapeutics.

[15]  Hubert Vesselle,et al.  FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine. , 2007, Seminars in nuclear medicine.

[16]  Pierre Dubus,et al.  Cdk1 is sufficient to drive the mammalian cell cycle , 2007, Nature.

[17]  Z. Chang,et al.  Mitotic control of dTTP pool: a necessity or coincidence? , 2007, Journal of biomedical science.

[18]  Steven P Gygi,et al.  A probability-based approach for high-throughput protein phosphorylation analysis and site localization , 2006, Nature Biotechnology.

[19]  Paul Workman,et al.  In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. , 2006, Cancer research.

[20]  E. Kinoshita,et al.  Phosphate-binding Tag, a New Tool to Visualize Phosphorylated Proteins*S , 2006, Molecular & Cellular Proteomics.

[21]  A. Shields,et al.  Positron Emission Tomography Measurement of Tumor Metabolism and Growth: Its Expanding Role in Oncology , 2006, Molecular Imaging and Biology.

[22]  S. Shousha,et al.  Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. , 2005, Cancer research.

[23]  P. Price,et al.  The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  E. Kinoshita,et al.  Novel immobilized zinc(II) affinity chromatography for phosphopeptides and phosphorylated proteins. , 2005, Journal of separation science.

[25]  Mark Muzi,et al.  Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  H. Eklund,et al.  Structures of thymidine kinase 1 of human and mycoplasmic origin , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Harris,et al.  Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine. , 2004, Biochimica et biophysica acta.

[28]  M. Muzi,et al.  Metabolism of 3'-deoxy-3'-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. , 2004, Nuclear medicine and biology.

[29]  Z. Chang,et al.  Perturbation of ATP-induced tetramerization of human cytosolic thymidine kinase by substitution of serine-13 with aspartic acid at the mitotic phosphorylation site. , 2004, Biochemical and biophysical research communications.

[30]  Z. Chang,et al.  Mitotic Degradation of Human Thymidine Kinase 1 Is Dependent on the Anaphase-Promoting Complex/Cyclosome-Cdh1-Mediated Pathway , 2004, Molecular and Cellular Biology.

[31]  P. Reichard,et al.  Origins of mitochondrial thymidine triphosphate: Dynamic relations to cytosolic pools , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A. Shields,et al.  PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  Qimin He,et al.  3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. , 2003, Cancer research.

[34]  Z. Chang,et al.  Degradation of human thymidine kinase is dependent on serine-13 phosphorylation: involvement of the SCF-mediated pathway. , 2003, The Biochemical journal.

[35]  Mark Muzi,et al.  In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  H. Dittmann,et al.  Early changes in [18F]FLT uptake after chemotherapy: an experimental study , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  L. Wiens,et al.  Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  G. Glatting,et al.  Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) in pancreatic cancer cell lines , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  Y. Yonekura,et al.  Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. , 2002, Nuclear medicine and biology.

[40]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[41]  Duen-Yi Huang,et al.  Serine 13 Is the Site of Mitotic Phosphorylation of Human Thymidine Kinase* , 1998, The Journal of Biological Chemistry.

[42]  G. Pfeifer,et al.  Constitutive Protection of E2F Recognition Sequences in the Human Thymidine Kinase Promoter during Cell Cycle Progression* , 1997, The Journal of Biological Chemistry.

[43]  Z. Chang,et al.  Differential phosphorylation of human thymidine kinase in proliferating and M phase-arrested human cells. , 1994, The Journal of biological chemistry.

[44]  W. Plunkett,et al.  Regulation of thymidine kinase and thymidylate synthase in intact human lymphoblast CCRF-CEM cells. , 1993, The Journal of biological chemistry.

[45]  B. Munch‐Petersen,et al.  Reversible ATP-dependent transition between two forms of human cytosolic thymidine kinase with different enzymatic properties. , 1993, The Journal of biological chemistry.

[46]  Duen-Yi Huang,et al.  The regulation of thymidine kinase in HL-60 human promyeloleukemia cells. , 1993, The Journal of biological chemistry.

[47]  S. Eriksson,et al.  Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. , 1991, The Journal of biological chemistry.

[48]  T. Kelly,et al.  Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis , 1991, Molecular and cellular biology.

[49]  J. Sherley,et al.  Regulation of human thymidine kinase during the cell cycle. , 1988, The Journal of biological chemistry.

[50]  I. Scheffler,et al.  Cell cycle-dependent regulation of thymidine kinase activity introduced into mouse LMTK- cells by DNA and chromatin-mediated gene transfer. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[51]  J. Steinkamp,et al.  RAPID, SIMULTANEOUS MEASUREMENT OF DNA, PROTEIN, AND CELL VOLUME IN SINGLE CELLS FROM LARGE MAMMALIAN CELL POPULATIONS , 1973, The Journal of cell biology.

[52]  E. Kinoshita,et al.  Separation and detection of large phosphoproteins using Phos-tag SDS-PAGE , 2009, Nature Protocols.

[53]  D O Morgan,et al.  Cyclin-dependent kinases: engines, clocks, and microprocessors. , 1997, Annual review of cell and developmental biology.

[54]  Elias S. J. Arnér,et al.  Mammalian deoxyribonucleoside kinases. , 1995, Pharmacology & therapeutics.